Small Doses of Subcutaneous Insulin as a Strategy for Preventing Slowly Progressive β-Cell Failure in Islet Cell Antibody—Positive Patients With Clinical Features of NIDDM
The DOI matches its Crossref record.
Abstract
We report a pilot study to determine the preventive effect of small doses of insulin injected subcutaneously on slowly progressive β-cell damage in islet cell antibody (ICA)-positive patients with apparent NIDDM. Ten NIDDM patients who were ICA+ were divided into two groups of five. In the insulin group (age: 51 ± 8 years [mean ± SD], sex: 3 men and 2 women), intermediate-type insulin (3–16 U/day) was given once or twice daily as a subcutaneous injection. The sulfonylurea (SU) group (age: 48 ± 11 years, sex: 3 men and 2 women) was initially treated with a SU agent. Changes in β-cell function, as indicated by serum C-peptide responses and blood glucose values during a 100-g oral glucose tolerance test, as well as ICA and GAD antibody status, were evaluated for up to 30 months in both groups. ICA status became negative in four of five patients in the insulin group. ICA status did not become negative in any of the patients in the SU group (P = 0.047 vs. insulin group). ICA status was persistently positive in two patients whose β-cell function eventually progressed to an insulin-dependent state and fluctuated in the remaining three patients. In the insulin group, GAD antibody status became negative in one of four initially GAD antibody–positive NIDDM patients. In the SU group, GAD antibody status was persistently positive in three NIDDM patients (NS vs. insulin group). The serum C-peptide response improved significantly within 6 and 12 months in the insulin group, whereas it decreased progressively in the SU group. The changes in C-peptide response were significantly different between the two groups at 6, 12, 24, and 30 months. Two-hour blood glucose and HbA1 values were unchanged in the insulin group, but they increased in the SU group. Subcutaneous small doses of insulin, resulting in a high rate of negative conversion of ICA and an improved serum C-peptide response, may be effective in treating ICA+ NIDDM patients who are at high risk for slowly progressive β-cell failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.161596 · Cited by 1,360
Sacks, D. B., Bruns, D. E., Goldstein, D. E., Maclaren, N. K., McDonald, J. M., & Parrott, M. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.3.436 · Cited by 1,130
Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491
Latent autoimmune diabetes in adults (LADA) should be less latent
Fourlanos, S., Dotta, F., Greenbaum, C. J., Palmer, J. P., Rolandsson, O., Colman, P. G., & Harrison, L. C. (2005) · Diabetologia · doi:10.1007/s00125-005-1960-7 · Cited by 401
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308
Metadata
- Authors
- Kobayashi, T., Nakanishi, K., Murase, T., & Kosaka, K.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1996-05-01
- Volume
- 45
- Issue
- 5
- Pages
- 622-626
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2162172210
- Cited by
- 149
- References
- 0
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small Doses of Subcutaneous Insulin as a Strategy for Preventing Slowly Progressive β-Cell Failure in Islet Cell Antibody—Positive Patients With Clinical Features of NIDDM. https://app.cochat.ai/papers/10.2337/diab.45.5.622
- The paper
- Kobayashi, T., Nakanishi, K., Murase, T., & Kosaka, K. (1996). Small Doses of Subcutaneous Insulin as a Strategy for Preventing Slowly Progressive β-Cell Failure in Islet Cell Antibody—Positive Patients With Clinical Features of NIDDM. Diabetes. https://doi.org/10.2337/diab.45.5.622
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.